Information for COVID-19 Therapeutics Providers

Texas Case Counts microscopic example of a coronavirus

This page contains information and resources for Texas COVID-19 therapeutics providers. Providers with questions can contact or call Provider Support at 833‑832‑7068, option 0.

On this page:

News & Updates

Update on Monoclonal Antibodies and the Omicron Variant

See the 1/03/22 DSHS letter to therapeutics providers (PDF) for an update on mAbs and the Omicron variant.

Using Therapeutics to Prevent and Treat COVID-19 (CDC HAN)

See the 12/31/21 CDC Health Alert Network communication for an update on using therapeutics to prevent and treat COVID-19.

Recently Authorized Therapeutics for COVID-19

See the 12/29/21 DSHS letter to therapeutics providers (PDF) for information on the recently authorized LAAB and oral antiviral therapeutics for COVID-19.

How to Become a COVID-19 Therapeutics Provider

To order COVID-19 therapeutics, providers must have an AmerisourceBergen Account and have access to the Vaccine Allocation Ordering System (VAOS).

For more information on the enrollment process, please review the COVID-19 Therapeutics Enrollment Guide (PDF).

If you have any questions or issues, please email or call Provider Support at 833‑832‑7068, option 0.

Therapeutics Products

Click on any of the buttons below to access a list of product-specific resources.

For the latest information on product distribution across the state, see the Texas COVID-19 Product Availability section.

Monoclonal Antibody (mAb) Products

Bamlanivimab + Etesevimab (Lilly) Casirivimab + Imdevimab (Regeneron) Sotrovimab (GlaxoSmithKline)

Long-Acting Antibody (LAAB) Product

Evusheld: tixagevimab + cilgavimab (AstraZeneca)

Oral Antiviral Products

Molnupiravir (Merck) Paxlovid: nirmatrelvir + ritonavir (Pfizer)

Provider Resources & Training

Important Links

Job Aid & FAQs


Texas COVID-19 Product Availability

Billing & Coding Information

▲ Top

This page is being updated as new information becomes available.

Last updated January 13, 2022